Reports

Ideas That Generate Results

List of Figures:

Figure 4-1: Global - API Market (Billion US$), 2013-2018
Figure 4-2: Global - Share of Captive and Merchant Market in API Market (2013)
Figure 4-3: Global - API Captive Market (Billion US$), 2013-2018
Figure 4-4: Global - API Merchant Market (Billion US$), 2013-2018
Figure 4-5: Global - Share of Branded and Generic APIs in API Merchant Market (2013)
Figure 4-6: Global - Generic API Merchant Market (Billion US$), 2013-2018
Figure 4-7: Global - Branded API Merchant Market (Billion US$), 2013-2018
Figure 4-8: Global - Share of Synthetic and Biotech APIs in API Market (2013)
Figure 5-1: Global - Price Structure for Pharmaceutical Fine Chemicals in US, India and China (%)
Figure 7-1: US - Pharmaceutical Sales (US$ Billion), 2013-2018
Figure 7-2: US - API Market (US$ Billion), 2013-2018
Figure 7-3: Japan - Pharmaceutical Sales (US$ Billion), 2013-2018
Figure 7-4: Japan - API Market (US$ Billion), 2013-2018
Figure 7-5: Italy - Pharmaceutical Sales (US$ Billion), 2013-2018
Figure 7-6: Italy - API Market (US$ Billion), 2013-2018
Figure 7-7: China- Pharmaceutical Sales (US$ Billion), 2013-2018
Figure 7-8: China- API Market (US$ Billion), 2013-2018
Figure 7-9: India Pharmaceutical Market (US$ Billion), 2013-2018
Figure 7-10: India - API Market (US$ Billion), 2013-2018
Figure 7-11: South Korea - Pharmaceutical Market (US$ Billion), 2013-2018
Figure 7-12: South Korea - API Market (US$ Billion), 2013-2018
Figure 7-13: Others - API Market (US$ Billion), 2013-2018
Figure 10-1: BASF SE - Break up of Revenue by Business Segment (%), 2013
Figure 10-2: BASF SE - Break up of Revenue by Geographic Segment (%), 2013
Figure 10-3: BASF SE - Chemicals - Break up of Revenue by Division (%), 2013
Figure 10-4: BASF SE - Intermediates- Break up of Revenue by Geographic Segment (%), 2013
Figure 10-5: Teva - Break up of Revenue by Geographical Segment (%), 2013
Figure 10-6: Teva - Break up of Revenue by Geographical Segment (%), 2013
Figure 10-7: Lonza - Break up of Revenue by Business Segment (%), 2013
Figure 10-8: Lonza - Break up of Revenue by Geographic Segment (%), 2013
Figure 10-9: DRL - Break up of Revenue by Business Segment (%), 2013
Figure 10-10: DRL - PSAI Break up of Revenue by Geographic Segment (%), 2013
Figure 10-11: Aurobindo Pharma Limited - Break up of Revenue by Business Segment (%), 2013
Figure 10-12: Aurobindo Pharma Limited - Break up of Revenue by Geographic Segment (%), 2013
Figure 10-13: Pfizer - Break up of Revenue by Business Segment (%), 2013
Figure 10-14: Pfizer - Break up of Revenue by Geographic Segment (%), 2013
Figure 10-15: Divis Laboratories - Break up of Revenue by Geographic Segment (%), 2013
Figure 10-16: Cambrex - Break up of Revenue by Geographic Segment (%), 2013
Figure 10-17: Royal DSM - Break up of Revenue by Business Segment (%), 2013
Figure 10-18: Royal DSM - Break up of Revenue by Geographic Origin (%), 2013
Figure 10-19: Boehringer - Break up of Revenue by Business Segment (%), 2013
Figure 10-20: Boehringer - Break up of Revenue by Geographic Segment (%), 2013

List of Tables:

Table 3-1: Classification of Bulk Drugs
Table 5-1: Global - Fine Chemical Industry Labor Cost and Productivity in Key Regions (2010)
Table 5-2: Global - Investment Cost Comparison for Multi-Purpose Pharmaceutical Fine Chemical Plants in Key Countries
Table 10-1: BASF SE - Key Financials (Million EUR), 2011-2013
Table 10-2: BASF SE- Strengths and Weaknesses
Table 10-3: Kyowa Hakko Kirin - Key Financials (Million Yen), 2011-2013
Table 10-4: Kyowa Hakko Kirin - Strengths and Weaknesses
Table 10-5: North China Pharmaceutical Group - Key Financials (Million Yuan), 2011-2013
Table 10-6: North China Pharmaceutical Group - Strengths and Weaknesses
Table 10-7: Teva Active Pharmaceutical Ingredients - Key Financials (Million USD), 2011-2013
Table 10-8: Teva Active Pharmaceutical Ingredients - Strengths and Weaknesses
Table 10-9: Northeast Pharmaceutical Group - Key Financials (Million Yuan), 2011-2013
Table 10-10: Northeast Pharmaceutical Group - Strengths and Weaknesses
Table 10-11: Lonza - Key Financials (Million CHF), 2011-2013
Table 10-12: Lonza - Strengths and Weaknesses
Table 10-13: DRL - Key Financials (Million Rupee), 2011-2013
Table 10-14: DRL - Strengths and Weaknesses
Table 10-15: Zhejiang Hisun Pharmaceutical - Key Financials (Million Yuan), 2011-2013
Table 10-16: Zhejiang Hisun Pharmaceutical - Strengths and Weaknesses
Table 10-17: Fabbrica Italiana Sintetici - Strengths and Weaknesses
Table 10-18: Aurobindo Pharma Limited - Key Financials (Million Rupee), 2011-2013
Table 10-19: Aurobindo Pharma Limited - Strengths and Weaknesses
Table 10-20: Pfizer - Key Financials (Million USD), 2011-2013
Table 10-21: Pfizer - Strengths and Weaknesses
Table 10-22: Divis Laboratories - Key Financials (Crore Rupee), 2011-2013
Table 10-23: Divis Laboratories Limited - Strengths and Weaknesses
Table 10-24: Cambrex - Key Financials (Million USD), 2011-2013
Table 10-25: Cambrex - Strengths and Weaknesses
Table 10-26: Royal DSM - Key Financials (Million EUR), 2011-2013
Table 10-27: Royal DSM - Strengths and Weaknesses
Table 10-28: Boehringer - Key Financials (Million EUR), 2011-2013
Table 10-29: Boehringer - Strengths and Weaknesses